Efficacy and safety of fezakinumab an IL22 monoclonal

Sign up to view full document!

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2 a trial Emma Guttman-Yassky, MD, Ph. D, Patrick M. Brunner, MD, Avidan U. Neumann, Ph. D, Saakshi Khattri, MD, Ana B. Pavel, Ph. D, Kunal Malik, BA, Giselle K. Singer, BS, Danielle Baum, Patricia Gilleaudeau, Mary Sullivan-Whalen, Sharon Rose, MD, Shelbi Jim On, MD, Xuan Li, BA, Judilyn Fuentes-Duculan, MD, Yeriel Estrada, BS, Sandra Garcet, Ph. D, Claudia Traidl-Hoffmann, MD, James G. Krueger, MD, Ph. D, Mark G. Lebwohl, MD Journal of the American Academy of Dermatology Volume 78 Issue 5 Pages 872 -881. e 6 (May 2018) DOI: 10. 1016/j. jaad. 2018. 016 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Journal of the American Academy of Dermatology 2018 78872 -881. e 6

Fig 1 Journal of the American Academy of Dermatology 2018 78872 -881. e 6 DOI: (10. 1016/j. jaad. 2018. 016) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Journal of the American Academy of Dermatology 2018 78872 -881. e 6

Fig 2 Journal of the American Academy of Dermatology 2018 78872 -881. e 6 DOI: (10. 1016/j. jaad. 2018. 016) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Journal of the American Academy of Dermatology 2018 78872 -881. e 6

Fig 3 Journal of the American Academy of Dermatology 2018 78872 -881. e 6 DOI: (10. 1016/j. jaad. 2018. 016) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 1 Journal of the American Academy of Dermatology 2018 78872 -881. e

Supplemental Fig 1 Journal of the American Academy of Dermatology 2018 78872 -881. e 6 DOI: (10. 1016/j. jaad. 2018. 016) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 2 Journal of the American Academy of Dermatology 2018 78872 -881. e

Supplemental Fig 2 Journal of the American Academy of Dermatology 2018 78872 -881. e 6 DOI: (10. 1016/j. jaad. 2018. 016) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 3 Journal of the American Academy of Dermatology 2018 78872 -881. e

Supplemental Fig 3 Journal of the American Academy of Dermatology 2018 78872 -881. e 6 DOI: (10. 1016/j. jaad. 2018. 016) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Slides: 7

Download presentation